Latest HeartWare International Inc. Stories
FRAMINGHAM, Mass. and SYDNEY, May 16, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2013 UBS Global Healthcare Conference at 11:00 a.m. EDT on Monday, May 20, 2013. The conference is being held May 20-22, 2013 at the Sheraton New...
FRAMINGHAM, Mass. and SYDNEY, May 10, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2013 Health Care Conference at 8:00 a.m. PDT (11:00 am EDT) on Thursday, May 16, 2013. The conference is being held...
- U.S. Revenues of $26.2 million, from $6.4 million in First Quarter of 2012; Reflecting First Complete Quarter of Commercialization in U.S. - FRAMINGHAM, Mass. and SYDNEY, April 29, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $49.2 million for the first quarter ended March...
FRAMINGHAM, Mass. and SYDNEY, April 15, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2013, at 5:00 p.m. U.S. Eastern Daylight Time on Monday, April 29, 2013. The Company plans to release the financial results prior to the conference call. The conference call with management will discuss the Company's financial results, highlights from the first quarter...
FRAMINGHAM, Mass. and SYDNEY, March 18, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the completion of a public offering of 1,725,000 shares of common stock, at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") on December 9, 2010. This amount includes 225,000 additional shares of common stock sold pursuant to the underwriters'...
FRAMINGHAM, Mass. and SYDNEY, March 12, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if...
FRAMINGHAM, Mass. and SYDNEY, March 11, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, 1,500,000 shares of common stock pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). HeartWare also intends to grant the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments,...
FRAMINGHAM, Mass., and SYDNEY, March 6, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2013 Global Healthcare Conference at 11:15 a.m. EDT on Tuesday, March 12, 2013. The conference is being held March 12-14, 2013 at the...
FRAMINGHAM, Mass. and SYDNEY, Feb. 28, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 34(th) Annual Institutional Investors Conference at 1:05 p.m. Eastern Standard Time on Tuesday, March 5, 2013. The conference is being...
- Fourth Quarter 2012 U.S. Revenue of $13.4 Million; 60% Increase from Fourth Quarter 2011; Reflects FDA Approval and First Month of Commercialization in U.S. - FRAMINGHAM, Mass. and SYDNEY, Feb. 27, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $32.7 million for the fourth...
